Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...

TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that haven't exactly been soaring, and thus its financial performance has ...

Scientists are using CRISPR to fast-track the domestication of a wild fruit. For roughly 10,000 years, farming communities ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

A miracle baby who was treated with a pioneering gene-therapy at CHOP has reached a major milestone as he took his first ...

CRISPR became big in 2025, bringing advances for serious Indian health risks, which will continue in the coming year ...

A child who received the world's first personalized CRISPR therapy is now taking his first steps after months in hospital ...

The world's first treatment that uses CRISPR gene-editing technology has been approved. Exa-cel, also known by its brand name Casgevy, received its first regulatory approval on Nov. 16, 2023 from the ...